Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

  1. Home
  2. Professionals
  3. Christopher M. Denig
  1. Back

Christopher M. Denig

Partner
Christopher Denig
Washington +1 202 662 5325 cdenig@cov.com Download V-card
View Less

Chris Denig represents companies, boards of directors, and senior executives in government enforcement matters, internal investigations, False Claims Act cases, and other litigation.

As a partner in the White Collar Defense & Investigations practice, Mr. Denig routinely represents clients before the U.S. Department of Justice, Securities & Exchange Commission, Congress, State Attorneys General, and other law enforcement and regulatory agencies. Mr. Denig has advised clients in the life sciences, financial services, defense, technology, and manufacturing industries on a variety of white collar matters including those relating to foreign bribery, corporate whistleblowers, accounting fraud, insider trading, export controls, and government contracting.

Pharmaceutical Investigations

  • Regularly represents major pharmaceutical and medical device companies in DOJ and State Attorney General investigations regarding cGMP issues, off-label promotion, kickbacks, state consumer protection/unlawful trade practices investigations, and related FCA matters.
  • Counsel to Indivior, Inc. in criminal investigation in the WDVA.
  • Counsel to a major pharmaceutical company in congressional hearings and other federal and state government investigations into OTC product recalls and cGMP issues and also in related consumer protection and other civil litigation.
  • Counsel to a medical device company in an unlawful trade practices investigation before a state AG.
  • Counsel to a major pharmaceutical company in its successful defense of a DOJ investigation concerning the promotion and marketing of a major drug resulting in a declination by DOJ and dismissal of a related FCA case.

False Claims Act and Other Litigation

  • Co-lead counsel to UnitedHealth Group subsidiary in ongoing False Claims Act litigation, Polansky v. Executive Health Resources (EDPA).
  • Represented McKesson Corporation in challenge to the use of a medication in lethal injection death penalty proceedings, as reported in the New York Times.
  • Represented more than 50 defendants in United States ex rel. Taylor v. Gabelli, et al. (SDNY), a significant FCA case involving allegations of fraud against the Federal Communications Commission.

SEC/Board Committee Matters   

  • Represented Audit Committee of a publicly-traded REIT in an internal investigation regarding accounting issues.
  • Represented Audit Committee of a natural foods company in an SEC investigation regarding inventory accounting issues.
  • Represented Special Litigation Committee of the Board of Hewlett-Packard Co. in shareholder derivative litigation arising out of the Board's response to leaks of confidential company information to the press.
  • Represented Audit Committee of one of the largest radio broadcasting companies in the United States in an SEC investigation of accounting practices relating to the dating of stock options.
  • Represented Special Committee of the Board of Tyco International, Ltd. regarding issues of corporate looting and accounting improprieties.
  • Represented Special Committee of the Board of Adelphia Communications Corp. regarding issues of corporate fraud being investigated by the U.S. Attorney’s Office in Manhattan and the SEC.
  • Represented Special Committee of the Board of a major computer company to investigate issues raised in shareholder derivative demand letter relating to alleged insider trading.
  • Mr. Denig also represents companies before the NASDAQ Listing Qualifications Panel.

Anti-Corruption, Foreign Trade Controls, and AKA Matters   

  • Regularly assists major companies in handling sensitive internal, whistleblower, and government anti-corruption investigations in Asia, South America, Africa, and Europe.
  • Assists major companies with internal investigations regarding foreign trade controls issues and making voluntary disclosures to the State Department.
  • Represented a major company in an AKA investigation by the DOJ, resulting in a declination.
  • Represented a large technology company in an OFAC investigation, resulting in a declination.

Anti-Corruption Compliance, Training, and Due Diligence   

  • Counsels companies on compliance with the FCPA, UK Bribery Act, and other anti-corruption laws, designs anti-corruption compliance and training programs, and provides companies with due diligence advice during corporate transactions.
View More View Less

Pro Bono

  • Has successfully led § 1983 actions against police and prosecutors in Louisiana arising out of wrongful convictions, Brady violations, and similar issues.
  • Successfully represented a putative class of deaf postal workers seeking sign language interpreters at safety and other important work meetings in the United States District Court for the District of Columbia and before the Equal Employment Opportunity Commission.

Memberships and Affiliations

  • The George Washington University Law School, Adjunct Professor of Law
View Less
  • Washington DC Super Lawyer, Criminal Defense: White Collar (2013; 2017-2019)

Practices

Columbia Law School, J.D.

Swarthmore College, B.A.

  • Hon. Richard M. Berman, U.S. District Court, Southern District of New York
  • District of Columbia
  • New York